openPR Logo
Press release

C Met Hgf Inhibitors Market Set to Witness an Uptick During 2017 - 2025

01-23-2018 08:40 AM CET | Health & Medicine

Press release from: Persistence Market Research

C Met Hgf Inhibitors Market Set to Witness an Uptick During 2017 -

c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.

Read Report Overview @ https://www.persistencemarketresearch.com/market-research/c-met-hgf-inhibitors-market.asp

c-Met kinase represents a novel target for cancer therapy and several research institutes and pharmaceuticals companies are engaged in developing new oncology drugs based on this inhibition of HGF or c-Met-dependent signaling pathway. Number of approaches being attempted to target c-Met include: c-Met biologic inhibitors, small molecule c-Met inhibitors, HGF antagonist antibodies, c-Met antagonist antibodies (MetMAb) and HGF kringle variant antagonists. A study undertaken by University of Heidelberg, Heidelberg, Germany demonstrated therapeutic potential of cabozantinib (Exelixis, Inc., Phase III) for against pancreatic ductal adenocarcinoma (PDA) and this molecule induced low-level of resistance compared to gemcitabine.

The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF. Several drugs are in developmental stage and underway clinical trials in various phases of clinical trials. Some of the prominent molecules include ARQ 197 (Arcule, Inc., Phase II), AV-299 (AVEO Pharmaceuticals, Inc., Phase II), cabozantinib (Exelixis, Inc., Phase III), JNJ-38877605 (Johnson & Johnson), PF04217903 (Pfizer, Inc., Phase I), PF02341066 (Pfizer, Inc., Phase II), GSK1363089 (GlaxoSmithKline plc), MK-2461 (Merck & Co., Phase II), MP470 (SuperGen, Inc., Phase I), and MGCD265 (Methylgene, Inc., Phase I), AMG102 (Amgen, Inc., Phase II), HuL2G7 (Galaxy Biotech, LLC) and MetMAb (Genentech, Inc., Phase I).

Request Report For TOC @ https://www.persistencemarketresearch.com/toc/21535

The global c-MET / HGF inhibitors market is yet to establish and hence every company is trying to expedite the research and development activity along with clinical trials. The larger multinationals are collaborating with companies having intellectual property rights but suffer from an insufficient capacity to commercialize the molecules. For instance, AstraZeneca signed a licensing deal with Hutchison MediPharma Ltd., to develop volitinib (HMPL-504/AZD6094) in non-small-cell lung carcinoma (NSCLC). Another recent development in the market was AVEO Oncology entering into a worldwide agreement with Biodexis in which latter company’s companion diagnostic test will be commercialized with AVEO’s ficlatuzumab (HGF inhibitory antibody).

Some of the companies having presence in the global c-MET / HGF inhibitors market are Abxign, Inc., Abbott Laboratories, Amgen, Inc., ArQule, Inc., Astex Therapeutics Ltd., AVEO Pharmaceuticals, Inc., Bristol-Myers Squibb (BMS) Co., Chroma Therapeutics Ltd., Daiichi Sankyo Co. Ltd., Deciphera Pharmaceuticals, LLC, Eisai Co., Ltd., Eli Lilly and Co., Exelixis, Inc., Genmab A/S, Galaxy Biotech, LLC, GlaxoSmithKline (GSK) plc, Hutchison MediPharma Ltd., Johnson & Johnson, Kringle Pharmaceuticals, Inc., Merck & Co., Methylgene, Inc., Novartis AG, Pfizer, Inc., ProMetic BioTherapeutics, Inc., and Takeda Pharmaceutical Co.

Request To Sample Of Report @ https://www.persistencemarketresearch.com/samples/21535

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA,Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release C Met Hgf Inhibitors Market Set to Witness an Uptick During 2017 - 2025 here

News-ID: 912562 • Views: 150

More Releases from Persistence Market Research

Polycaprolactone Market Estimated To Experience A Hike In Growth By 2026
Polycaprolactone, a biodegradable polymer, is gaining widespread traction considering its value-adding properties including high flexibility, hydrophobic nature, molecular weight distribution, and low viscosity. Moreover, deepening production of thermoplastic Polyurethane, Polyurethane (PU), and Polyols would also contribute the increased consumption of polycaprolactone. Thermoplastic polyurethane would remain the largest category with close to 45% share of the polycaprolactone market. A study by Persistence Market Research projects the polycaprolactone market to exhibit a promising
Isostearyl Alcohol Market by Top Brands, Trends and Demand 2024
The chemical industry is focused to keep the business operations running along with ensuring the labor safety amid the COVID-19 pandemic. To recover the losses created by the decline in demand for various products, the companies are capitalizing on the escalating demand for products such as disinfectants and personal protective equipment. Many leading players in the chemical industry have expanded their business to enter into the production of safety products.
The Automatic Biopsy Systems market to stand in a good stead from 2019 to 2029
A biopsy is a method in which body tissue separated from any organ of the body for the diagnosis of disease. In some cases, the tissue is removed by using the simple needles and in some cases tissue removed by surgical methods. Automatic biopsy systems perform a highly accurate clinical intervention since most of the Automatic biopsy machines work under image guidance. Robotic automatic biopsy systems is the latest novel
Home Care Chemicals Market by Top Brands, Trends and Demand By 2020 End
The impact of COVID-19 pandemic can be felt across the chemical industry. The growing inability in the production and manufacturing processes, in the light of the self-quarantined workforce has caused a major disruption in the supply chain across the sector. Restrictions encouraged by this pandemic are obstructing the production of essentials such as life-saving drugs. Request For Report Sample@ https://www.persistencemarketresearch.com/samples/4528 The nature of operation in chemical plants that cannot be easily stopped

All 5 Releases


More Releases for HGF

Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019 | …
Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis. Download the sample report @ https://www.pharmaproff.com/request-sample/1201 Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed
c-MET/HGF Inhibitors Market Production and CAGR (%) Comparison by Types
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
C-MET / HGF Inhibitors Global Market 2019 Top Key Players – Abxign,  Abbott L …
Global C-MET / HGF Inhibitors Market WiseGuyRerports.com Presents Global C-MET / HGF Inhibitors Market Insights, Forecast to 2025” New Document to its Studies Database. The Report Contain 148 Pages With Detailed Analysis. Description c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during
c-MET / HGF Inhibitors Market to Record an Exponential CAGR by 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
c-MET / HGF Inhibitors Market to Register Steady Growth During 2017- 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
HGF Family Day Empowers Florida Families with Children with Growth Disorders
Human Growth Foundation will host “HGF Family Day” on Saturday, September 24, 2016, at Sea World, from 9:00 am – 6:00 pm, in Orlando, Florida. The nonprofit event is in celebration of National Growth Awareness Week and will engage, educate and empower local families whose children have growth disorders. HGF Family Day will include workshops to learn about the latest developments in growth disorders, combating bullying, and obtaining medical insurance